WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development
WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) today announced the signing of strategic Memoranda of...
SHA: 603259
WuXi AppTec Sells WuXi Clinical and MedKey to Hillhouse for RMB 2.8 Billion
WuXi AppTec (Shanghai) Co., Ltd., a wholly‑owned subsidiary of Wuxi AppTec Co., Ltd. (SHA: 603259,...
Wuxi Apptec Reports 15.3 % YoY Revenue Growth in Q3 2025, Net Profit Hits RMB 4.22 Billion
Wuxi Apptec Co., Ltd. (SHA: 603259, HKG: 2359) today announced third‑quarter 2025 financial results, delivering...
Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development
China‑based Corxel Pharmaceuticals (CORXEL) and WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), have...
Wuxi Apptec Reports Strong Q2 2025 Results with 20.6% Revenue Growth
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) announced strong growth in...
JW Therapeutics’ Carteyva Receives Fourth sBLA for r/r LBCL
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...
WuXi AppTec Reports 21.0% YOY Revenue Growth in Q1 2025
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) released its financial report...
WuXi XDC Partners with MABSOFT to Advance Innovative ADC Development
China-based WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi...
WuXi XDC Reports 90.8% Revenue Surge, Expanding in ADC Market
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...
WuXi AppTec Reports Steady Revenue Growth Amid Diversified Business Expansion
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) released its 2024 financial...
WuXi XDC and AbTis Partner to Advance Antibody-Drug Conjugate Innovation
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...
WuXi XDC Expands MOU with LigaChem to Advance Next-Gen ADC Development
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
NAMSA to Acquire WuXi AppTec’s US Medical Device Testing Business
US-based medical device contract research organization (CRO) NAMSA is set to acquire the medical device...
WuXi Biologics to Sell Irish Vaccine Assets to MSD for USD 500 Million
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) is poised to...
WuXi AppTec to Divest WuXi Advanced Therapies and Oxford Genetics to Altaris LLC
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259) has announced...
WuXi AppTec’s Subsidiary Invests EUR 20 Million in Jeito II S.L.P. for Growth Expansion
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259) has announced...
GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reportedly withdrawn...
WuXi AppTec Reports Q3 2024 Revenues of RMB 10.46 Billion Amid Biosecure Act Challenges
WuXi AppTec Co., Ltd (SHA: 603259), the China-based Contract Development and Manufacturing Organization (CDMO) facing...
WuXi AppTec Addresses Media Speculation on Potential Sale of WuXi ATU
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359, OTCMKTS: WUXAY), a leading China-based Contract Development...
WuXi XDC Reports 67.6% YOY Revenue Growth and Expands Manufacturing with Singapore Plant
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...